drugset / Trial / NCT05788081
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
Phase 2
Active not recruiting
40 enrolled
Olivia Newton-John Cancer Research Institute
Austin Health · collabBarwon Health · collabBristol-Myers Squibb · collabEastern Health · collabFiona Stanley Hospital · collabGrampians Health · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
First line treatment with combination rituximab and golcadomide with, or without nivolumab, in patients in previously untreated Follicular Lymphoma
Timeline
- Start
- 2023-08-31
- Primary completion
- 2027-01-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golcadomide | Other / unclassified | 0.4 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |